Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Immunocore Holdings (IMCR) Operating Expenses (2023 - 2025)

Immunocore Holdings' Operating Expenses history spans 3 years, with the latest figure at $39.8 million for Q3 2025.

  • For Q3 2025, Operating Expenses fell 24.62% year-over-year to $39.8 million; the TTM value through Dec 2025 reached $96.2 million, down 67.93%, while the annual FY2025 figure was $274.9 million, 27.27% down from the prior year.
  • Operating Expenses for Q3 2025 was $39.8 million at Immunocore Holdings, down from $56.5 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $96.7 million in Q1 2024 and bottomed at $35.5 million in Q3 2023.
  • The 3-year median for Operating Expenses is $58.7 million (2024), against an average of $61.6 million.
  • The largest annual shift saw Operating Expenses soared 48.78% in 2024 before it crashed 41.63% in 2025.
  • A 3-year view of Operating Expenses shows it stood at $41.4 million in 2023, then soared by 46.81% to $60.8 million in 2024, then plummeted by 34.63% to $39.8 million in 2025.
  • Per Business Quant, the three most recent readings for IMCR's Operating Expenses are $39.8 million (Q3 2025), $56.5 million (Q1 2025), and $60.8 million (Q4 2024).